Status:
COMPLETED
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
Lead Sponsor:
Ting YANG
Conditions:
Hematologic Malignancies
Hematologic Disorders
Eligibility:
All Genders
Brief Summary
This study reviews patients who received haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Some patients develop donor-specific antibodies (DSA), which can block engraftment and cau...
Detailed Description
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective, and often the only curative, treatment for many malignant and non-malignant hematologic diseases. Haploidentical HSCT (h...
Eligibility Criteria
Inclusion
- Patients who received haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) from a related donor (≥5/10 HLA match).
- Presence of donor-specific anti-HLA antibodies (DSA) before transplantation, with mean fluorescence intensity (MFI) above the positive threshold.
- Underwent desensitization therapy mainly based on protein A immunoadsorption (with or without additional agents such as rituximab or bortezomib), with complete treatment records.
- Successfully completed transplantation at the study center and had at least 100 days of follow-up.
Exclusion
- Missing critical data (e.g., incomplete DSA results, desensitization details, or follow-up outcomes).
- Inadequate follow-up (patients lost to follow-up or transferred to another hospital without accessible records).
- Patients who did not complete desensitization or did not undergo HSCT infusion.
Key Trial Info
Start Date :
May 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07200583
Start Date
May 31 2025
End Date
August 31 2025
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001
Fuzhou, Fujian, China